|
1.
|
|
18 p, 1.4 MB |
Dickkopf Proteins and Their Role in Cancer : A Family of Wnt Antagonists with a Dual Role
/
Giralt, Irina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallo-Oller, Gabriel (Vall d'Hebron Institut d'Oncologia) ;
Navarro Barea, Natalia (Vall d'Hebron Institut d'Oncologia) ;
Zarzosa, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Pons, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Magdaleno, Ainara (Vall d'Hebron Institut d'Oncologia) ;
Segura, Miguel F. (Vall d'Hebron Institut d'Oncologia) ;
Sánchez de Toledo, José (Vall d'Hebron Institut d'Oncologia) ;
Moreno, Lucas (Hospital Universitari Vall d'Hebron) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron) ;
Roma, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The Wnt signaling pathway regulates crucial aspects such as cell fate determination, cell polarity and organogenesis during embryonic development. Wnt pathway deregulation is a hallmark of several cancers such as lung, gastric and liver cancer, and has been reported to be altered in others. [...]
2021 -  10.3390/ph14080810
Pharmaceuticals, Vol. 14 (august 2021)
|
|
|
2.
|
|
14 p, 2.6 MB |
Analysis of Cancer Genomic Amplifications Identifies Druggable Collateral Dependencies within the Amplicon
/
Pons, Guillem (Hospital Universitari Vall d'Hebron) ;
Gallo-Oller, Gabriel (Hospital Universitari Vall d'Hebron) ;
Navarro Barea, Natalia (Hospital Universitari Vall d'Hebron) ;
Zarzosa, Patricia (Hospital Universitari Vall d'Hebron) ;
Sansa-Girona, Júlia (Hospital Universitari Vall d'Hebron) ;
García-Gilabert, Lia (Hospital Universitari Vall d'Hebron) ;
Magdaleno, Ainara (Hospital Universitari Vall d'Hebron) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron) ;
Sánchez de Toledo Codin, Josep (Hospital Universitari Vall d'Hebron) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron) ;
Moreno, Lucas (Hospital Universitari Vall d'Hebron) ;
Roma, Josep (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
The identification of novel therapeutic targets for specific cancer molecular subtypes is crucial for the development of precision oncology. In the last few years, CRISPR/Cas9 screens have accelerated the discovery and validation of new targets associated with different tumor types, mutations, and fusions. [...]
2023 - 10.3390/cancers15061636
Cancers, Vol. 15 (march 2023)
|
|
|
3.
|
|
17 p, 1.1 MB |
Targeting the Hedgehog Pathway in Rhabdomyosarcoma
/
Zarzosa, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Gilabert, Lia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hladun, Raquel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Guillén, Gabriela (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallo-Oller, Gabriel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Pons, Guillem (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sansa-Girona, Julia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sánchez de Toledo Codin, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreno, Lucas (Vall d'Hebron Institut d'Oncologia) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca)
In the first sections of this review, we provide a comprehensive description of the Hedgehog signalling pathway in mammals and the main general models of pathway activation. Subsequently, the review focuses on the oncogenic role played by this pathway in rhabdomyosarcoma and the inhibitors developed to date, as well as the clinical trials available in sarcomas. [...]
2023 - 10.3390/cancers15030727
Cancers, Vol. 15 (january 2023)
|
|
|
4.
|
|
13 p, 1.6 MB |
MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma
/
Vella, Serena (Ospedale Pediatrico Bambino Gesù) ;
Pomella, Silvia (Istituto Dermopatico dell'Immacolata) ;
Leoncini, Pier Paolo (Ospedale Pediatrico Bambino Gesù) ;
Colletti, Marta (Ospedale Pediatrico Bambino Gesù) ;
Conti, Beatrice (Ospedale Pediatrico Bambino Gesù) ;
Marquez, Victor E. (Frederick National Laboratory for Cancer Research) ;
Strillacci, Antonio (University of Bologna) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Milano, Giuseppe M. (Ospedale Pediatrico Bambino Gesù) ;
Capogrossi, Maurizio C. (Istituto Dermopatico dell'Immacolata) ;
Bertaina, Alice (Ospedale Pediatrico Bambino Gesù) ;
Ciarapica, Roberta (Istituto Dermopatico dell'Immacolata) ;
Rota, Rossella (Laboratory of Angiogenesis, Ospedale Pediatrico Bambino Gesù) ;
Universitat Autònoma de Barcelona
Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma arising from myogenic precursors that have lost their capability to differentiate into skeletal muscle. The polycomb-group protein EZH2 is a Lys27 histone H3 methyltransferase that regulates the balance between cell proliferation and differentiation by epigenetically silencing muscle-specific genes. [...]
2015 - 10.1186/s13148-015-0107-z
Clinical Epigenetics, Vol. 7 (august 2015)
|
|
|
5.
|
|
12 p, 2.0 MB |
DAX-1 Expression in Pediatric Rhabdomyosarcomas : Another Immunohistochemical Marker Useful in the Diagnosis of Translocation Positive Alveolar Rhabdomyosarcoma
/
Virgone, Calogero (University Hospital of Padova (Pàdua, Itàlia)) ;
Lalli, Enzo (Université de Nice-Sophia Antipolis) ;
Bisogno, Gianni (University Hospital of Padova (Pàdua, Itàlia)) ;
Lazzari, Elena (San Bortolo Hospital, Vicenza) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Zin, Angelica (Istituto della Ricerca Pediatrica "Città della Speranza") ;
Poli, Elena (Istituto della Ricerca Pediatrica "Città della Speranza") ;
Cecchetto, Giovanni (University Hospital of Padova (Pàdua, Itàlia)) ;
Dall'Igna, Patrizia (University Hospital of Padova (Pàdua, Itàlia)) ;
Alaggio, Rita (University of Padua) ;
Universitat Autònoma de Barcelona
The aim of this study was to investigate the expression of DAX-1 in a series of pediatric rhabdomyosarcomas (RMS) with known translocation and compare it to Ap2β, known to be selectively expressed in ARMS. [...]
2015 - 10.1371/journal.pone.0133019
PloS one, Vol. 10 (july 2015)
|
|
|
6.
|
|
13 p, 2.2 MB |
Both Epimutations and Chromosome Aberrations Affect Multiple Imprinted Loci in Aggressive Wilms Tumors
/
Pignata, Laura (Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso') ;
Palumbo, Orazio (Fondazione IRCCS "Casa Sollievo della Sofferenza") ;
Cerrato, Flavia (University of Campania 'Luigi Vanvitelli') ;
Acurzio, Basilia (Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso') ;
De Álava, Enrique (Universidad de Sevilla) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Català-Mora, Jaume (Hospital Sant Joan de Déu (Manresa)) ;
Carella, Massimo (Fondazione IRCCS "Casa Sollievo Della Sofferenza") ;
Riccio, Andrea (Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso') ;
Verde, Gaetano (Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso') ;
Universitat Autònoma de Barcelona
About 7% of all children's malignancies are represented by the embryonal renal cancer Wilms tumor (WT). Since methylation imprinting alterations at multiple loci dictated by chromosome copy-number variations have been recently demonstrated in adult cancers, we investigated the presence of similar alterations in pediatric malignancies. [...]
2020 - 10.3390/cancers12113411
Cancers, Vol. 12 (november 2020)
|
|
|
7.
|
|
10 p, 1.7 MB |
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis
/
París-Coderch, Laia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Erazo, Tatiana (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Muñoz-Guardiola, Pau (Ability Pharmaceuticals) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Boloix, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Alfón, José (Ability Pharmaceuticals) ;
Pérez-Montoyo, Héctor (Ability Pharmaceuticals) ;
Yeste-Velasco, Marc (Ability Pharmaceuticals) ;
Domènech, Carles (Ability Pharmaceuticals) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sánchez de Toledo Codin, Josep (Vall d'Hebron Institut d'Oncologia) ;
Moreno, Lucas (Vall d'Hebron Institut d'Oncologia) ;
Lizcano de Vega, José Miguel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Gallego, Soledad (Vall d'Hebron Institut d'Oncologia) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Neuroblastoma is the leading cause of cancer death in children aged 1 to 4 years. Particularly, five-year overall survival for high-risk neuroblastoma is below 50% with no curative options when refractory or relapsed. [...]
2020 - 10.1038/s41419-020-02986-w
Cell death and disease, Vol. 11 (september 2020)
|
|
|
8.
|
|
13 p, 1.3 MB |
Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
/
Alcon, Clara (Institut de Bioenginyeria de Catalunya) ;
Manzano-Muñoz, Albert (Institut de Bioenginyeria de Catalunya) ;
Prada, Estela (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Català-Mora, Jaume (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Guillén, Gabriela (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Samitier, Josep (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Villanueva, Alberto (Institut d'Investigació Biomèdica de Bellvitge) ;
Montero, Joan (Institut de Bioenginyeria de Catalunya) ;
Universitat Autònoma de Barcelona
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. [...]
2020 - 10.1038/s41419-020-02887-y
Cell death and disease, Vol. 11 (august 2020)
|
|
|
9.
|
|
17 p, 3.9 MB |
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models
/
Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Riley, Misha (Massachusetts General Hospital (Boston)) ;
Servidei, Tiziana (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Riccardi, Riccardo (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martini, Maurizio (Catholic University of Sacred Heart) ;
Ruggiero, Antonio (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Moreno, Lucas (Vall d'Hebron Institut d'Oncologia) ;
Sánchez de Toledo Codin, Josep (Vall d'Hebron Institut d'Oncologia) ;
Gallego, Soledad (Vall d'Hebron Institut d'Oncologia) ;
Bové, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hooker, Jacob M. (Massachusetts General Hospital (Boston)) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Pediatric ependymoma (EPN) is a highly aggressive tumor of the central nervous system that remains incurable in 40% of cases. In children, the majority of cases develop in the posterior fossa and can be classified into two distinct molecular entities: EPN posterior fossa A (PF-EPN-A) and EPN posterior fossa B (PF-EPN-B). [...]
2020 - 10.3390/cancers12071922
Cancers, Vol. 12 (july 2020)
|
|
|
10.
|
|
1.1 MB |
Long Non-coding RNA PVT1 as a Prognostic and Therapeutic Target in Pediatric Cancer
/
Boloix, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sánchez de Toledo Codin, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
In recent decades, biomedical research has focused on understanding the functionality of the human translated genome, which represents a minor part of all genetic information transcribed from the human genome. [...]
2019 - 10.3389/fonc.2019.01173
Frontiers in Oncology, Vol. 9 (november 2019)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
